NASDAQ
02.04.25
21:47 Uhr
0,980 US-Dollar
0,000
0,00 %
0,00 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Shattuck Labs GAAP EPS of -$0.37 | 1 | Seeking Alpha | ||
| Fr | Shattuck Labs (NASDAQ:STTK) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS | 1 | MarketBeat | ||
| Fr | H.C. Wainwright holds Shattuck Labs stock at Neutral | 2 | Investing.com | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 27.03. | Shattuck Labs, Inc Loss At -$18.68 Mln In Q4 | 1 | RTTNews | ||
| 27.03. | Shattuck Labs, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.03. | Shattuck Labs, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights | 333 | GlobeNewswire (Europe) | - Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class... ► Artikel lesen | |
| 27.03. | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Shattuck Labs, Inc. (NASDAQ:STTK) Receives Average Recommendation of "Moderate Buy" from Brokerages | 1 | MarketBeat | ||
| 17.03. | Leerink initiates Shattuck Labs stock with Outperform, $4 target | 2 | Investing.com | ||
| 20.02. | Shattuck Labs berichtet über positive präklinische Daten für SL-325 | 2 | Investing.com Deutsch | ||
| 13.02. | Shattuck Labs, Inc.: Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 | 2 | GlobeNewswire (USA) | ||
| 04.02. | Shattuck Labs, Inc.: Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress | 2 | GlobeNewswire (USA) | ||
| 02.01. | Shattuck Labs gears up for DR3 antagonist trials in 2025 | 2 | Investing.com | ||
| 02.01. | Shattuck Labs, Inc.: Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 | 110 | GlobeNewswire (Europe) | AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor... ► Artikel lesen | |
| 07.12.24 | Redmile Group verkauft Aktien von Shattuck Labs im Wert von 166.713 US-Dollar | 5 | Investing.com Deutsch | ||
| 14.11.24 | Shattuck Labs GAAP EPS of -$0.33 beats by $0.06, revenue of $3M | 1 | Seeking Alpha | ||
| 14.11.24 | Shattuck Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.24 | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 26.10.24 | Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Down 60.0% in October | 1 | MarketBeat |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,00 | -2,58 % | Biontech-Partner unter Druck: Schwerer Vorwurf an Pfizer: War der Covid-Impfstoff viel früher ready? | © Foto: picture alliance/pressefoto_korb/Micha Korb - pressefoto_korb picture alliance/pressefoto_korb/Micha KorbIm Zentrum steht die Frage: Hat Pfizer die Bekanntgabe des Erfolgs seines gemeinsam mit... ► Artikel lesen | |
| BB BIOTECH | 31,350 | -1,72 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
| BIOVENTUS | 9,510 | +1,49 % | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results | Accelerated fourth quarter sales growth to 13.5%Fourth quarter gross margin expanded 310 bps and adjusted gross margin* expanded 230 bpsFourth quarter cash from operations of $19.3 million increased... ► Artikel lesen | |
| CG ONCOLOGY | 22,430 | +1,72 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| 89BIO | 7,190 | +5,81 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 37,760 | +6,04 % | Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results | Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990)... ► Artikel lesen | |
| DISC MEDICINE | 48,500 | +2,86 % | Disc Medicine Inc: Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025Positive... ► Artikel lesen | |
| AMGEN | 282,30 | 0,00 % | P/E Ratio Insights for Amgen | ||
| QIAGEN | 36,980 | +0,19 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
| IMMUNOME | 6,710 | +7,36 % | Hedge Fund and Insider Trading News: Michael Hintze, Stanley Druckenmiller, Bill Ackman, Eisler Capital, Immunome Inc (IMNM), and More | ||
| 2SEVENTY BIO | 4,955 | +0,10 % | Pre-market Movers: 2seventy bio, Sonoma Pharmaceuticals, Tenon Medical, Arvinas, NET Power Inc. | LONDON (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green 2seventy bio, Inc. (TSVT) is up over 76% at $4.93.
Sonoma... ► Artikel lesen | |
| GUBRA | 59,80 | -0,33 % | AKTIONÄR-Depotwert Gubra: Im Sog von Novo Nordisk - Daten voraus | Die Aktie des dänischen Biopharma-Riesen Novo Nordisk fällt und fällt. Der Abverkauf geht auch an kleineren Playern im Adipositas-Bereich nicht spurlos vorbei. So auch beim AKTIONÄR-Depotwert Gubra:... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 4,425 | -0,11 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors | Results from dose escalation arms of Phase 1/2 study of MRT-2359 demonstrated a favorable safety profile and targeted levels of GSPT1 degradation using a 21 days on, 7 days off drug dosing schedule... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 11,640 | +14,57 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results | Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 17,970 | -0,11 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Full Year 2024 Financial Results | First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib... ► Artikel lesen |
Das Unternehmen SHATTUCK LABS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,980 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.
